Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture

Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture

Approximately 10,000 cases of tick-borne encephalitis (TBE), a serious disease of the central nervous system caused by tick-borne encephalitis virus (TBEV), are registered worldwide every year. Vaccination against TBE remains the most essential measure of preventing the disease. Unlike available TBE...

Full description

Bibliographic Details
Main Authors: Mikhail F. Vorovitch, Karina G. Grishina, Viktor P. Volok, Liubov L. Chernokhaeva, Konstantin V. Grishin, Galina G. Karganova, Aidar A. Ishmukhametov
Format: Article
Language:English
Published: Taylor & Francis Group 2020-09-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
inactivated vaccine
tick-borne encephalitis
tick-borne encephalitis vaccine
reactogenicity
immunogenicity
vaccine safety
flavivirus
Online Access:http://dx.doi.org/10.1080/21645515.2020.1757990

Internet

http://dx.doi.org/10.1080/21645515.2020.1757990

Similar Items